|
|
Previous Article | Table of Contents | Next Article 
Blood, 1 July 2002, Vol. 100, No. 1, pp. 341-343
BRIEF REPORT
Activated platelets of patients with paroxysmal nocturnal
hemoglobinuria express cellular prion protein
Karel Holada,
Jan Simak,
Antonio M. Risitano,
Jaroslaw Maciejewski,
Neal S. Young, and
Jaroslav G. Vostal
From the Laboratory of Cellular Hematology, Division of
Hematology, Center for Biologics Evaluation and Research, Food and Drug
Administration, and the Hematology Branch, National Heart, Lung, and
Blood Institute, National Institutes of Health, Bethesda, MD.
Cellular prion protein (PrPc) is a glycosylphosphatidylinositol
(GPI)-anchored membrane glycoprotein that contains a putative membrane-spanning section. Patients with paroxysmal nocturnal hemoglobinuria (PNH) lack GPI proteins on the surface of somatically mutated hematopoietic stem cell and its progeny. Platelet expression of
PrPc was studied in 8 PNH patients. Resting PNH (CD55 )
platelets were devoid of surface PrPc, but activation of platelets resulted in the surface expression of PrPc. Expressed PrPc was detected
by 2 monoclonal antibodies (mAbs) against the N-terminal part of the
molecule but not by mAb 6H4, which binds at the C-terminus beyond the
membrane-spanning section. However, 6H4 detected PrPc on Western blots
of PNH platelets, demonstrating that the lack of 6H4 binding was not
caused by PrPc truncation. Our results indicate that in the absence of
GPI anchor, PrPc can be expressed intracellularly and up-regulated on
the platelet membrane, likely in a transmembrane form with the
C-terminal part of the molecule inserted into the cytoplasm.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. Linden, V. R. Martins, M. A. M. Prado, M. Cammarota, I. Izquierdo, and R. R. Brentani
Physiology of the Prion Protein
Physiol Rev,
April 1, 2008;
88(2):
673 - 728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Villagra, S. Shiva, L. A. Hunter, R. F. Machado, M. T. Gladwin, and G. J. Kato
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin
Blood,
September 15, 2007;
110(6):
2166 - 2172.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J Franklin, A Pluetschow, M Paus, L Specht, A-P Anselmo, A Aviles, G Biti, T Bogatyreva, G Bonadonna, C Brillant, et al.
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials
Ann. Onc.,
December 1, 2006;
17(12):
1749 - 1760.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Josting, L. Nogova, J. Franklin, J.-P. Glossmann, H. T. Eich, M. Sieber, T. Schober, H.-D. Boettcher, U. Schulz, R.-P. Muller, et al.
Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin's Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group
J. Clin. Oncol.,
March 1, 2005;
23(7):
1522 - 1529.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Vassella, P. Butikofer, M. Engstler, J. Jelk, and I. Roditi
Procyclin Null Mutants of Trypanosoma brucei Express Free Glycosylphosphatidylinositols on Their Surface
Mol. Biol. Cell,
April 1, 2003;
14(4):
1308 - 1318.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|